Dr Reddy's polypill beats strong after FDA panel view
This article was originally published in Scrip
Executive Summary
Polypill developers can take heart that the route to the US market may have become feasible after the US FDA's Cardiovascular and Renal Drugs Advisory Committee offered cautious support to such fixed dose combinations in prevention of secondary CV events.